secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0000950170-25-079876
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics reports updated Phase 1/2a data for [212Pb]VMT-α-NET in NETs at ASCO 2025
--------------------------------------------------------------------------------

- No dose-limiting toxicities, no discontinuations due to AEs, and no Grade 4/5 TEAEs in 42 treated patients.
- Four of seven patients in Cohort 2 had objective responses per RECIST v1.1; three confirmed, one pending confirmation.
- Seven of nine patients from Cohorts 1 and 2 remained progression-free after more than one year of follow-up.
- Safety acceptable: low-grade hematologic toxicities; all creatinine increases Grade 1; no serious renal complications.
- Cohort 2 re-opened in Aug 2024; 33 additional patients enrolled; company engaging FDA for further dose finding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017025079876/0000950170-25-079876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017025079876/catx-20250530.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-079876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer